UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

Biochemical journal, 2008-01, Vol.409 (2), p.581-589

2008

Volltextzugriff (PDF)

The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo

Cancer chemotherapy and pharmacology, 2007-07, Vol.60 (2), p.275-283

2007

Volltextzugriff (PDF)

A drug response predictor to guide treatment for breast cancer

Pharmacogenomics, 2019-04, Vol.20 (5), p.307-309

2019

Volltextzugriff (PDF)

Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts

PloS one, 2018-03, Vol.13 (3), p.e0194609-e0194609

2018

Volltextzugriff (PDF)

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

European journal of haematology, 2008-09, Vol.81 (3), p.170-176

2008

Volltextzugriff (PDF)

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

Clinical cancer research, 2008-02, Vol.14 (3), p.804-810

2008

Volltextzugriff (PDF)

Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study

Breast cancer research and treatment, 2018-11, Vol.172 (2), p.391-400

2018

Volltextzugriff (PDF)

Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data

PloS one, 2016-05, Vol.11 (5), p.e0155123

2016

Volltextzugriff (PDF)

Clinical Impact of a Novel MicroRNA Chemo-Sensitivity Predictor in Gastrooesophageal Cancer

PloS one, 2016-02, Vol.11 (2), p.e0148070-e0148070

2016

Volltextzugriff (PDF)

Anticancer agent CHS-828 inhibits cellular synthesis of NAD

Biochemical and biophysical research communications, 2008-03, Vol.367 (4), p.799-804

2008

Volltextzugriff (PDF)

Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer

PloS one, 2017-03, Vol.12 (3), p.e0174300

2017

Volltextzugriff (PDF)

Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay

Breast cancer (Tokyo, Japan), 2020-03, Vol.27 (2), p.266-276

2020

Volltextzugriff (PDF)

Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PET

PloS one, 2013-12, Vol.8 (12), p.e85126-e85126

2013

Volltextzugriff (PDF)

[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts

PloS one, 2013-01, Vol.8 (1), p.e53410

2013

Volltextzugriff (PDF)

Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice

PloS one, 2010-09, Vol.5 (9), p.e12965

2010

Volltextzugriff (PDF)

Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane

Cancer chemotherapy and pharmacology, 2012-02, Vol.69 (2), p.573-576

2012

Volltextzugriff (PDF)

[18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice

PloS one, 2012-11, Vol.7 (11), p.e50618

2012

Volltextzugriff (PDF)

Predicting epirubicin response in Danish patients with breast cancer

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.539-539

2024

Volltextzugriff (PDF)

Novel small molecule drugs inhibit tumor cell metabolism and show potent anti-tumorigenic potential

Cancer chemotherapy and pharmacology, 2011-07, Vol.68 (1), p.127-138

2011

Volltextzugriff (PDF)

Dexrazoxane Protects against Myelosuppression from the DNA Cleavage–Enhancing Drugs Etoposide and Daunorubicin but not Doxorubicin

Clinical cancer research, 2005-05, Vol.11 (10), p.3915-3924

2005

Volltextzugriff (PDF)

Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone

Cancer chemotherapy and pharmacology, 2006, Vol.57 (1), p.125-128

2006

Volltextzugriff (PDF)

Treatment of Anthracycline Extravasation with Dexrazoxane

Clinical cancer research, 2000-09, Vol.6 (9), p.3680-3686

2000

Volltextzugriff (PDF)

Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3130-3130

2023

Volltextzugriff (PDF)

Doxorubicin response prediction in neoadjuvant breast cancer therapy

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e12119-e12119

2019

Volltextzugriff (PDF)

Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx ® ): a placebo-controlled randomised phase II study (PLIANT)

Acta oncologica, 2018-01, Vol.57 (3), p.393-402

2018

Volltextzugriff (PDF)

1 – 25 von 114

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(107)
Mit Volltextzugriff
(106)

Publikationsform

Artikel
(113)
Bücher
(1)

Sprache

Englisch
(111)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo

A drug response predictor to guide treatment for breast cancer

Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study

Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data

Clinical Impact of a Novel MicroRNA Chemo-Sensitivity Predictor in Gastrooesophageal Cancer

Anticancer agent CHS-828 inhibits cellular synthesis of NAD

Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer

Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay

Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PET

[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts

Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice

Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane

[18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice

Predicting epirubicin response in Danish patients with breast cancer

Novel small molecule drugs inhibit tumor cell metabolism and show potent anti-tumorigenic potential

Dexrazoxane Protects against Myelosuppression from the DNA Cleavage–Enhancing Drugs Etoposide and Daunorubicin but not Doxorubicin

Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone

Treatment of Anthracycline Extravasation with Dexrazoxane

Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer

Doxorubicin response prediction in neoadjuvant breast cancer therapy

Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx ® ): a placebo-controlled randomised phase II study (PLIANT)

Suchergebnisse filtern